Beta-Amyloid [31-35] polyclonal, anti-human, mouse, rat

Protein Family: Proteoglycans

Pathway and Disease: Neurodegenerative Disorders

Description:
Beta-amyloid production results from cleavage in the extracellular domain of APP by the beta-secretase (BACE1) , which results in the production of the APP C-terminal fragment C99. This fragment is further cleaved by the gamma-secretase at residues 40-42 to produce beta-amyloid 40 and 42 peptides. Beta-amyloid aggregation and neuritic plaque formation are pathologic hallmarks of Alzheimer disease.

Alternate Names: Beta-Amyloid [31-35], APP, ABPP, Alzheimer disease amyloid protein, Cerebral vascular amyloid peptide, CVAP, Protease nexin-II, PN-II, APPI, PreA8, Beta-amyloid protein 40, Beta-APP40

Application Notes: E: 1:500-1:1,000; WB: 1:100-1:500; IHC: 1:100-1:500

Accession No.: P05067

Antigen: KLH-conjugated synthetic peptide encompassing a sequence within human b-amyloid 31-35.

Format: Each vial contains 0.1 mg IgG in 0.1 ml (1 mg/ml) of PBS pH7.4 with 0.09% sodium azide. Antibody was purified by Protein-G affinity chromatography.

Storage:
Store at -20°C. Minimize freeze-thaw cycles. Product is guaranteed one year from the date of shipment.